Subclinical atherosclerosis and endothelial dysfunction in patients with polymyalgia rheumatica: a pilot study

Area of Science:

• Rheumatology
• Vascular Biology
• Clinical Immunology

Background:

• Polymyalgia rheumatica (PMR) is a chronic inflammatory condition.
• Endothelial dysfunction is increasingly recognized in inflammatory diseases.
• The impact of PMR on endothelial function and its response to treatment requires further elucidation.

Purpose of the Study:

• To investigate endothelial function in treatment-naïve polymyalgia rheumatica (PMR) patients.
• To assess the modification of endothelial function during steroid therapy.
• To correlate changes in endothelial function with clinical and laboratory parameters.

Main Methods:

• Prospective observational study of 16 newly diagnosed PMR patients and 16 matched controls.
• Evaluation of brachial artery flow-mediated dilatation (FMD) as a measure of endothelial function.
• Clinical and vascular ultrasound assessments at baseline and at 1, 3, 6, and 12 months during steroid therapy.

Main Results:

• PMR patients showed significantly lower FMD compared to controls at baseline.
• Endothelial dysfunction persisted for up to 6 months of steroid therapy, despite clinical improvement.
• FMD values inversely correlated with erythrocyte sedimentation rate and C-reactive protein levels.

Conclusions:

• PMR is associated with significant chronic subclinical inflammation and endothelial dysfunction.
• Endothelial dysfunction in PMR demonstrates a slow response to standard steroid therapy.
• Further research is warranted to understand the clinical implications and cardiovascular risk in PMR.